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Glycolysis inhibition targets
In its simplest description, apoptosis is a cell death process largely regulated by the Bcl-2 family that is composed of antiapoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, A1...) as opposed to pro-apoptotic members (Bax, Bak, Bim...). 1 Overexpression of anti-apoptotic members is among the best-characterized cause of apoptosis resistance. The anti-apoptotic activity of some proteins of this family can now be manipulated pharmacologically, using 'BH3-mimetic' molecules, such as ABT-737, which inhibit the interaction with pro-apoptotic counterparts. 2 Numerous phase I trials in solid and hematological cancers, including non-Hodgkin's lymphoma, are underway to assess the effects of navitoclax, an orally available BH3-mimetic. However, as it is the case with most chemotherapeutic agents, a number of cancer cells do not respond to ABT-737 mainly because this compound cannot appreciably bind to Mcl-1 or A1.
2 Therefore, identifying a way to modulate the sensitivity to ABT-737 could represent an innovative method to sensitize resistant tumor cells to this agent.
Recently, we established that an inhibition of the glycolytic metabolism of transformed cells could decrease Mcl-1 levels, but no other Bcl-2 anti-apoptotic members, through a control of its translation. 3 In the present work, we therefore investigated, using human cell lines, primary murine cells and in vivo, whether inhibiting glycolysis may restore sensitivity to ABT-737-induced death. As Mcl-1 is overexpressed in many cancers, including B-and T-cell malignancies, 4 we therefore evaluated the sensitivity of several B non-Hodgkin's (NH) lymphoma cell lines (Ramos, Raji, BJAB) to ABT-737-mediated apoptosis. As expected, all three cell lines were resistant to this BH3-mimetic, as opposed to the sensitive T leukemic cell line, Jurkat (Figure 1a Mice life span following the beginning of the treatment is indicated for each groups (number of mice/group n ¼ 8 for vehicle, n ¼ 6 for 2DG, n ¼ 5 for ABT and n ¼ 8 for ABT þ 2DG). The statistical comparison was done using the non-parametric logrank test (Mantel --Cox test, P ¼ 0.0091). In addition, we compared the median survival of each group (using Mann --Whitney test) and observed that PBS, 2DG and ABT groups were not significantly different, whereas the (ABT-2DG) group is indeed significantly different (*Po0.05) from all the others. (e) Lymph nodes were harvested from 3 independent mice treated with PBS, 2DG, ABT-737 or ABT-737 þ 2DG. Mcl-1 expression was analyzed by immunoblots. HSP60 was used as a loading control.
Letters to the Editor from Em-myc mice. Those transgenic mice are overexpressing the c-myc oncogene in the B-cell lineage and develop pre-B and B lymphomas similar to human non-Hodgkin's lymphomas. 5 As presented in Figure 1b , WT MEF and primary cells isolated from five independent Em-myc mice were resistant to ABT-737-induced apoptosis whereas Mcl-1 À/À MEFs were sensitive to its cytotoxic effect. Here again the sensitivity or resistance of the cells to ABT-737 was strictly correlated with Mcl-1 level of expression (Figure 1b, insert) .
To evaluate the effect of glycolysis inhibition on Mcl-1 expression, Ramos or primary Em-myc cells were incubated with two potent hexokinase (HK) inhibitors: 2-deoxyglucose (2DG) or Lonidamine (LND) each leading to a B40% reduction of lactate production (not shown). As shown in Figure 1c , 2DG and LND were able to lead to a reduction from 20 to 70% of Mcl-1 expression in Ramos as in primary Em-myc cells. Mcl-1 reduction was mediated through a metabolic control of its translation rates rather than a change of its stability (not shown), which is consistent with our recent publication. 3 As glycolysis inhibition could decrease Mcl-1 levels in NH-B lymphoma cells, we evaluated whether HK inhibitors could enhance ABT-737-induced apoptosis in these cells. We treated ABT-sensitive (Jurkat) or ABT-resistant cells (Ramos or primary Em-myc clones) with an increasing amount of the Bcl-2/Bcl-xL inhibitor in the presence of a defined amount of HK inhibitor. For all tested cell lines, glycolysis inhibition using 2DG (Figure 2a) or LND (Figure 2b ) can enhance ABT-737-induced apoptosis. Indeed, ABT-737 toxicity was increased by more than eightfold in primary Em-myc cells in the presence of HK inhibitors (8.8 ± 0.4 vs 75.5±0.4% of cell death in 5 mM ABT-737 vs ABT-737 þ LND). Of note, neither 2DG nor LND presented a significant toxicity on their own.
To confirm that the resistance of Ramos cell to ABT-737 was dependent on the high level of Mcl-1 expression and not on an overexpression of an other anti-apoptotic member not targeted by this BH3-mimetic (as A1), we downregulated Mcl-1 expression in those cells using siRNA (Figure 2c, insert) . As presented in Figure 2c , Mcl-1 knockdown was sufficient to sensitize Ramos cells to ABT-737-induced apoptosis to the same extent as the incubation with LND, suggesting that the glycolytic control of the Mcl-1 level was the key step to sensitize cells to ABT-737-induced cytotoxicity.
We finally evaluated the impact of the co-treatment in vivo. For that matter, WT C57BL6 mice were injected i.v. with syngenic Em-myc cells. Upon lymphoma's apparition mice were treated daily for 12 days either with vehicle, 2DG, ABT-737 or ABT-737 þ 2DG and mice life span was measured. We established that the median survival of co-treated mice significantly increased by 50% compared with single-agent-treated mice (14 or 15 days in PBS, 2DG, or ABT-737, respectively, compared with 22 days in the ABT þ 2DG group; Figure 2d) . By analyzing Mcl-1 level in three independent mice from each group, we could confirm that glycolysis inhibition (±ABT-737) led to a decrease in Mcl-1 in vivo compared with control groups and that it correlated with the extended mice life span observed in the co-treated mice. Of note, the further reduction of Mcl-1 levels observed in co-treated animals is consistent with the fact that the co-treatment will increase apoptosis (Figure 2a) and that, in this condition, Mcl-1 will be further cleaved by caspases. 6 Novel small molecules that target Bcl-2 anti-apoptotic members have shown promising in vitro and preclinical activity in multiple tumors. 7 --9 Mimicking the BH3-only protein Bad, ABT-737 can efficiently inhibit some but not all prosurvival members, including Mcl-1, therefore, being inefficient for cell harboring significant levels of this anti-apoptotic member as NH-lymphomas. Among the Bcl-2 family, Mcl-1 is very particular as it has a short half-life and an enhanced reliance on continued translation. Therefore, it is very affected by condition than can control cellular translation, including modification of cell metabolism. 10, 11 In the present work, we have described the potentialization of ABT-737-induced cell death by HK inhibitors via the downregulation of Mcl-1 levels in NH-lymphoma cells. Even if changes in Mcl-1 expression were partial, these were sufficient to enhance ABT-737-induced cytotoxicity in vitro and to further protect mice in vivo. Knowing that both inhibitors are currently in clinical trials and that they are overall well tolerated by patients, 12 it is suggested that such combination has the potential to be developed against ABT-737-resistant malignancies. 
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